WO2018202864A1

WO2018202864A1 - Method for detecting an immune cellular response

Info

Publication number: WO2018202864A1
Application number: PCT/EP2018/061533
Authority: WO
Inventors: Yasemin Ataman-Onal; Michel Arnaud; Franck BERTHIER; Jacqueline DUPRET-CARRUEL; Jacques PASSAGOT
Original assignee: bioMérieux
Priority date: 2017-05-05
Filing date: 2018-05-04
Publication date: 2018-11-08
Also published as: US20200191771A1; EP4124862A1; EP3619533A1; ES2933132T3; EP3619533B1

Abstract

The present invention relates to a method for detecting an immune cellular response in a biological sample of animal origin, that may contain at least one cell which secretes at least one immune effector molecule, comprising the steps consisting in: (a) suctioning a defined amount of the biological sample as taken by means of an automated suction/discharge device, (b) discharging this defined amount, using said automated suction/discharge device, into a container R, said container R containing, beforehand, at least one stimulant for secretion of said molecule by said at least one cell, or else said container R not containing such an at least one stimulant, (c) when the container does not contain, beforehand, at least one secretion stimulant, introducing into said container R said at least one secretion stimulant contained in a container E, using said automated suction/discharge device, and (d) allowing the defined amount of sample and said at least one stimulant to incubate, forming a mixture, for the secretion of said molecule by said at least one cell (i) in said container R or (ii) in another container S after suctioning and discharge of said mixture using said automated suction/discharge device, and (e) detecting the immune cellular response, in which the detection of the immune cellular response indicates the presence of an immune cellular response specific for said at least one secretion stimulant.

Description

Method for detecting an immune cell response

The present invention relates to the field of detection of immune cellular responses. In particular, the invention relates to a new method for detecting an immune cell response in a biological sample, said response being useful both in the field of diagnosis and in the field of therapy, especially for toxicity studies of future drugs. and vaccines.

The field of detection of immune cell responses has been a growing field in recent years. Thus, with the development of the ELIspot test (Enzyme-linked immunospot) in the 1980s, originally used to measure the secretion of immunoglobulins by the B cells of a human body, then expanded to all circulating blood cells capable of to secrete a molecule after their stimulation in vitro, even present in a small quantity, a wide medical field of application has opened, notably to better understand and follow the immune response, for example in the context of infectious diseases or auto diseases - immune, and in the field of cancer (Cox JH et al., 2006).

The immune response, caused by the entry of an antigen into an organism, is of two kinds: it is either a humoral immune response or a cell-mediated immune response. The humoral immune response, which comprises adaptive immunity to antibody production, consists of four main steps: antigen recognition and clonal selection, clonal proliferation, differentiation of B cells into plasma cells that will secrete immunoglobulins (also called antibodies), thereby forming immune complexes to neutralize the antigen. This response acts against extracellular microorganisms. The cell-mediated immune response, also called cellular immune response or CMI (Cell-Mediated Immunity) response, is the adaptive immunity in which T cells (also called T cells) play a central role by activating a whole cascade of signals and responses to infection or aggression, such as the production of cytokines. The effector cells of cell-mediated immunity, such as cytotoxic T lymphocytes, act against microorganisms. These two types of "humoral" immune responses or "to Cellular mediation "implements cells secreting molecules, called immune effector molecules, ie antibodies or cytokines, including chemokines.

The antigens causing this immune response may be of infectious origin, exogenous, for example because of pathogens such as viruses, bacteria, fungi or parasites, or because of allergens, or of endogenous origin, for example in the context of autoimmune diseases such as multiple sclerosis, type 1 diabetes, lupus, autoimmune thyroiditis, rheumatoid arthritis, ankylosing spondylitis, Goujerot-Sjögren's syndrome, Crohn's disease, cancerous diseases, etc.

The multiplication of a pathogen within the body, or the release with pathogen-related preserved motifs ([PAMPs]) as well as the release of danger signals during trauma, burns or surgery, for example, are responsible for an immune and inflammatory reaction. This reaction has a humoral slope and a cellular slope. Moreover, in all these situations, it associates a pro-inflammatory response (which is considered today to be responsible for the occurrence of organ failure and early mortality), as well as an anti-inflammatory response. inflammatory, which, when it persists, is responsible for an immunosuppression phase, as found in immunosuppressed patients, and places patients at risk for secondary infections.

Apart from these acute pathologies, other alterations of the immune balance are responsible for pathologies. Thus, chronic inflammatory diseases highlight an imbalance of the response in favor of excessive activation of the immune system, with chronic destruction of the impacted tissues, and the occurrence of a loss of function of the affected organ. In contrast, situations of innuendo immunodepression (immune deficiency) or acquired (infection with the AIDS virus, chemotherapy, immunosuppression induced during organ transplantation, for example) underline an insufficient response of the immune system with a infectious risk and increased tumor formation.

Detection of effector molecules produced by immune cells ex vivo makes it possible to improve patient management, whether to help diagnose these conditions or to guide / personalize the therapeutic management.

Tests to detect the cell-mediated immune response (CMI) can be used in various immunology disciplines. For example, MIC assays can detect donor-reactive circulating T cells during organ transplantation; to measure the activity of cytotoxic T lymphocytes for cancer research; measure memory responses for infectious diseases or vaccine development; and to detect self-reactive cells (which are typically low frequency) in autoimmune diseases. The ELIspot test can also be used in the preclinical phase to determine if a product tested could elicit an undesirable immune response, before using it on humans.

The method of detecting the immune cell response comprises two phases:

1) Phase 1 - Secretion: Incubation of the cells of interest from a biological sample containing them and likely to secrete the molecule to be detected, under conditions allowing the secretion of the molecule. We can then speak for this stage of "cell culture" or "stimulation". The cells are cultured in a liquid medium, this liquid medium can be either a biological fluid (that of the sample), pure or diluted in a buffer, or a culture medium, or a mixture of both. This secretion is obtained in the presence of a stimulant, this stimulant being specific, as in the case of immune responses directed against an infectious agent, or which may be nonspecific, as for example in the case of cellular immune responses due to a deficiency. immune.

2) Phase 2 - Detection of the immune cell response: it can be implemented by detection or quantification of the secreted molecule at the end of phase 1 (instead we speak of an analyte) by implementing a dosage of the secreted molecule, by any type of technique adapted to the detection of secreted molecules, such as by immunoassay, for example of the ELISA type (Enzyme-Linked Immunosorbent Assay), RIA, chemiluminescence or ELFA (Enzyme-Linked Fluorescent Assay), by bioassay, or by biochemical technique, by proliferation assay, by molecular biology test or by flow cytometry.

An example of an infectious pathology in which the diagnosis takes into account the detection of the immune cell response due to cells of the infected organism is tuberculosis. For several decades, the only test available was the cuti test. This one makes it possible to know if the tested individual has been in contact with the bacillus Mycobacterium tuberculosis. To do this, the doctor performs an intra-dermo reaction to bring the immune cells of the individual into contact with a tuberculin preparation. The latter causes an inflammatory response (cuti- reaction) in patients who have been in contact with the Mycobacterium tuberculosis bacillus (presence of redness at the injection). However, the realization of the technique is complex and the reading of the result is subjective and requires the expertise of the caregiver. Moreover, this test does not make it possible to quantify the secreted cytokines.

There are two commercial blood tests that show whether patients have been in contact with the Mycobacterium tuberculosis bacillus by measuring in vitro the release of interferon gamma (IFN-γ) by the cells in response to stimulants that are highly specific antigens of Mycobacterium tuberculosis. In particular, these stimulating antigens are at least ESAT6 and CFP10 and are absent from BCG vaccine (Bacille Calmette-Guerin) and most non-tuberculous mycobacteria (Lalvani, A., 2007). These tests are called IGRA (Interferon Gamma Release Assay) tests.

The first test is Oxford Immunotec's T-SPOT®.TB test [Oxford, UK], a blood ELISpot assay that measures cytokine release from isolated cells. For this test, the blood sample is first taken from a laboratory in a sterile heparinized tube, for example a Vacutainer® tube (Becton-Dickinson) or a Greiner tube, Terumo tube, Sarstedt tube, etc. PBMC cells (peripheral blood mononuclear cells) are then separated from the whole blood by several Ficoll density gradient centrifugation steps, washed and counted. For each blood sample, the resulting PBMCs are cultured in a plate of microtiter (also called microplate) under 3 different conditions: (i) in the presence of specific stimulation antigens (eg ESAT-6, CFP-10), (ii) in the presence of one or more non-specific mitogens (positive control) and (iii) in the presence of the stimulation medium only (negative control). The microplates thus prepared are incubated under conditions permitting the secretion of IFN-gamma, for example at 37 ° C., 5% CO _2, in a cell culture oven for 16 to 20 hours. This step of introducing the secretory cells and cell culture is carried out under a laminar flow host in order to maintain sterile conditions during cell culture. The last step is to detect the cytokine thus secreted using an anti-IFN-gamma capture antibody previously applied to the bottom of the microtiter plate, a detection partner binding to the cytokine and a substrate, thus forming accounting spots on the membrane, each spot corresponding to a secretory cell. The principle of such an ELIspot assay is described for example in Handbook of Elispot, 2005, and in particular on page 17. This test has the drawback that it is manual, that it requires purification (separation) PBMC from whole blood using one or more centrifugation steps, as well as the use of special equipment (laminar flow hood) to ensure sterility to transfer the blood sample to the plate and during cell culture. In addition, this test is a complex, high-tech test requiring well-trained technical staff.

The second test is the QuantiFERON®-TB Gold [Qiagen] test, which measures the total concentration of IFN-γ released by all cells in the supernatant of a blood sample by ELISA. In this test, the blood sample must be taken directly from the patient into three specific sterile blood collection tubes, one containing the stimulation antigens (ESAT-6, CFP-10, and TB7.7), the other containing a mitogen (positive control) and the last tube being the so-called NIL tube (negative control). Then, the tubes, always sterile, are incubated at 37 ° C for 16 to 24 hours to allow the secretion of interferon gamma, so that the stimulation step takes place in sterile condition. The tubes are then centrifuged, the plasma removed and pipetted into a microplate containing an anti-IFN-gamma capture antibody. The amount of IFN-gamma is then measured by ELISA at using a revealing partner and an enzymatic substrate. This test has several disadvantages. First of all this test is not automated. It requires centrifugation, like the T-SPOT® test, so it is not easily automated. In addition, since the blood collection tubes used already contain the stimulation antigens, interferon-gamma-secreting cells are immediately put in contact with these stimulation antigens, resulting in a particular and restrictive manipulation until the dosage of the IFN-γ. Indeed, it is necessary to place these tubes at room temperature (22 +/- 5 ° C) to slow down the secretion, and perform the assay of IFN-gamma within a given time from the contact between the blood and the cells. stimulants (16h maximum). This is also detrimental to the reproducibility of the results: depending on the organizational constraints of the laboratories, the delay between the collection of the sample and the stimulation at 37 ° C for the secretion can vary greatly. Finally, as indicated previously, this test implements particular sterile sampling tubes, not only containing the stimulation antigens beforehand, but different according to the altitude at which the assays are performed (different tube references), which is more difficult from a stock management point of view for a laboratory compared to the use of conventional sterile tubes, as for the T-SPOT® test.

Of course, tuberculosis is not the only pathology for which cell tests are used, as noted above. In addition, these tests are also used for other mammals (Wood P.R., 1990).

However, whatever the test, a major disadvantage, besides the difficulty of automation due to the necessity of a centrifugation step, is related to the lack of reproducibility (Pal M. et al, 2014). This lack of reproducibility is explained by several factors, of which one important is the sample volume which may be different from one blood sample to another. This has the consequence of reducing the sensitivity of the tests (Gaur RL, et al, 2013). The fluctuation of the sample volume is due to the taking of blood sample carried out using the tubes used, which are under vacuum, with a depression calculated to take about 1 ml of blood, ie between 0.8 and 1.2 ml. Thus, the ratio of stimulating antigens of the specific tube / volume of blood is different from one sample to another, which necessarily has an impact on the amount of secreted cytokine and therefore the reproducibility of its measurement. Being able to have a system that would always take exactly the same amount of sample would overcome this disadvantage.

Almeida CA. M. et al, 2009 propose an automated ELIspot test after PBMC purification by centrifugation, including cell counting and spot counting. To do this, they use sample handling robotics and reagents and an integrated information system to electronically track the performance of the assay. This test is in fact only partially automated because the automation does not include the preparation of PBMC and the introduction of stimulation peptides in the 96-well plates. In addition, this test includes particular steps, either before automation, such as a centrifugation step of the sample to separate the cells, which is difficult to automate, or during automation, such as a step of counting cells.

Neubauer J.C. et al, 2017 propose a more automated ELIspot test after purification of PBMCs by centrifugation, ranging from cell counting to spot counting to cell culture (stimulation for secretion by cells). This is the use of a Tecan type pipetting robot to automate the cell distribution steps, different reagents and washing solutions. However, this solution requires at least two particular and expensive equipment, which would make mass production complicated. Indeed, this automation requires in particular the use of a laminar flow hood above all the automation device to respect the sterility during cell culture, a requirement and which forms the basis of the cell culture (Coligan JE, 1994). Finally, as with the test of Almeida CA. M. et al, 2009, particular steps are necessary, (i) before this automation, such as a centrifugation step of the sample to separate the cells, which is, as indicated previously, difficult to automate, (ii) during the automation, such as a step of counting the cells.

The Applicant has surprisingly found that it is possible to overcome the disadvantages of the methods of the prior art and to proceed to the detection of the response. immune cell by automating the cell stimulation step which is done directly in the biological sample to be tested as taken, and thus unmodified after sampling, without resorting to either a centrifugation step, or a step of separating the cells. cells, or a step of counting the cells, which greatly simplifies the automated instruments to implement for such an automated detection.

Also, the invention relates to a method for detecting an immune cell response in a biological sample of animal origin, capable of containing at least one secretory cell of at least one immune effector molecule, comprising the steps of:

(a) aspirating a defined quantity of the biological sample as taken by an automated suction / discharge device,

(b) repressing this defined quantity, by means of said automated suction / discharge device, into a container R, said container R containing at least one secretory stimulant of said molecule by said at least one cell or said container R not containing such at least one stimulant,

(c) when the container does not contain at least one secretory stimulant, introducing into said container R with the aid of said automated suction / discharge device, said at least one secretion stimulant contained in a container E, and

(d) incubating the defined amount of sample and said at least one stimulant, forming a mixture, for the secretion of said molecule by said at least one cell (i) in said container R or (ii) in another container S after suctioning and discharging said mixture using said automated suction / discharge device, and

(e) detecting the immune cell response, wherein the detection of the immune cell response indicates the presence of a specific immune cell response of the at least one secretory stimulant.

As indicated above, the method for detecting the immune cell response of the invention can be divided into two phases: a phase of stimulation of the secretory cells or capable of secreting at least one effector molecule immunity, contained in a biological sample of animal origin, for the secretion of said molecule (steps (a) to (d)) and a phase of detecting said response after stimulation (step (e)). Also, the invention also relates to the first phase, namely an automated method for stimulating at least one cell capable of secreting an immune effector molecule for the secretion of said molecule, said at least one cell being derived from a biological sample of animal origin, characterized in that it comprises or consists of the steps of:

(d) incubating the defined amount of sample and said at least one stimulant, forming a mixture, for the secretion of said molecule by said at least one cell (i) in said container R or (ii) in another container S after aspiration and discharge of said mixture with the aid of said automated suction / discharge device.

The immune cell response thus obtained is particularly useful in various medical applications. Also the invention also relates to the use of the method for detecting the immune cell response of the invention or the automatic stimulation method of the invention for the diagnosis of pathologies, for toxicity studies of drugs and vaccines and for determining the immune status of a patient.

The Applicant has unexpectedly found that it is possible to greatly improve the detection of the immune cell response in a biological sample of animal origin likely to contain at least one cell. secretory of at least one immune effector molecule by automating the step of stimulating the cells directly in the biological sample to be tested, which has never been modified after sampling, for example having never undergone or a centrifugation step , in particular for separating the cells before or after stimulation, or a step of counting the cells as in the context of an ELIspot assay and having never been in contact with a stimulation stimulant. This has many advantages including, among others, the use of a simple automated instrument, the implementation of standard sampling tubes of the biological sample, that is to say containing no prior stimulant and suitable at any implementation condition, such as lithium heparin-containing tubes, better control of the total time between bringing the sample into contact with the stimulant (s) and the detection of the immune cell response, as well as that control of the sample volume for cell stimulation.

By immune cell response is meant both the cell-mediated immune response and the humoral immune response generated after stimulation of the secretory cells or capable of secreting an immune effector molecule with at least one secretory stimulant, which cells are contained in a biological sample.

Cells contained in the biological sample and capable of secreting at least one immune effector molecule include effector cells of cell-mediated immunity, for example lymphocytes such as Natural Killer (NK) cells and T cells (CD4 + and or CD8 +), which secrete one or more cytokines, the humoral mediated immunity effector cells, for example B cells, which secrete antibodies, macrophages and monocytes, and dendritic cells, which secrete cytokines. or chemokines. As indicated above, these immune cells are capable of secreting the molecules of interest in the presence of one or more secretory stimulants.

By secretion stimulant is meant any element which causes the secretion by the cell, brought into contact with this stimulant, an immune effector molecule which is a protein such as cytokine, antibody or marker, or an AR transcript of the gene of the invention. immune effector molecule. By "RNA transcript" is meant RNA, and in particularly the messenger ARs, resulting from the transcription of the gene of the immune effector molecule. Depending on the immune response that one wishes to obtain, related to the pathological state concerned, which is itself linked or not to a pathogenic microorganism, the stimulant will be specific pathogenic or non-specific microorganism, which constitutes an embodiment particular of the invention. In contrast to the specific stimulant of a pathogen, any other stimulant that is nonspecific for either nonspecific stimulant or nonspecific stimulant of a pathogen may be used interchangeably.

Thus, for pathological conditions not related to a pathogenic microorganism, such as for example autoimmune diseases (for example multiple sclerosis, type 1 diabetes, lupus, autoimmune thyroiditis, rheumatoid arthritis, ankylosing spondylitis, Goujerot-Sjôgren's syndrome, Crohn's disease), trauma including severe trauma including several traumatisms such as poly-lesions such as wound, fracture, burn, etc., grafts, the method of the invention can put one or more nonspecific stimulants, also called mitogens, such as protein kinase A (PKA), phorbol myristate acetate (PMA), phytohemagglutin (PHA), concanavalin A (conA), mitogen Pokeweed (PWM) Staphylococcal enterotoxin B (SEB) and lipopolysaccharide (LPS).

For pathological conditions related to a pathogenic microorganism, for example virus-related disease states such as acquired immunodeficiency syndrome (HIV virus, SIV, IVF), hepatitis (HCV virus, HBV, HAV, HEV), chickenpox (VZV virus), cytomegalovirus-related infections (CMV), infectious mononucleosis (EBV), various herpes-like infections (HSV1 virus, HSV2), pathological conditions related to bacteria such as tuberculosis (Mycobacterium tuberculosis Mycobacterium bovis, Mycobacterium leprae), Lyme disease (Borrelia - Borrelia burgdorferi stricto sensu, Borrelia afzelii, Borrelia garinii, Borrelia spielmanii), Clostridia infections (eg Clostridium difficile, Clostridium botulinum), Salmonella, Pneumonia and others pathologies of the respiratory system (eg Klebsiella, Leugionella), urinary diseases (Proteus, Klebsiella), intestinal infections (eg Escheric hia coli, Shigella), nosocomial infections (eg Pseudomonas aeruginosa, Staphylococcus aureus) or syphilis (Treponema pallidum), yeast-related conditions such as candidiasis (Candida albicans), fungal infections such as aspergillosis (Aspergillus fumigatus), and mucormycoses (Mucorales), parasite-related pathologies such as malaria (Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi), Schistosomiasis (Schistosomia mansoni, Schistosomia japonicum), the stimulant will be specific for the pathogen. It will comprise at least one pathogen-specific antigen resulting in the cells from the biological sample producing either a cytokine or an antibody to that antigen, depending on the nature of the stimulated cells.

Examples of pathogen-specific stimulants include peptide molecules (proteins or parts of proteins) that may be derived from the pathogen, for example from the envelope as part of a virus, or they may be secreted by the pathogen itself. These molecules can be used whole or in the form of peptide fragments of variable length, for example at least 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids and not more than the entire protein, or not more than 30, 35, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 amino acids. The method of the invention may use one or more peptide stimulants of equal or different amino acid length. For example, it can use at least one peptide stimulant of length between 7 and 15 amino acids and at least one other peptide stimulant of at least 16 amino acids and at most the entire protein. The method of the invention may use one or more stimulants from different strains of pathogen.

When a vaccine exists, the specific stimulants used may not be those present in the vaccine to then allow use of the method of the invention in diagnostic applications, for example to verify in the vaccinated patient if he has been in contact with the pathogen. The composition of the vaccines is known so that it is easy for those skilled in the art to select the appropriate pathogen-specific antigenic stimulants.

Specific pathogen stimulants are well known to humans job. By way of non-limiting examples, mention may be made of PPD (Protein Purified Derivate) stimulator, ESAT-6, CFP-10, TB7.7, TB37.6, Rv3615c proteins or fragments thereof for the pathogen Mycobacterium tuberculosis (EP2154248 A , EPI 144447A, EP2417456A), the proteins pp28, pp50, pp65, IE-1, IE-2, gB or fragments thereof for the pathogen Cytomegalovirus and peptides Pep Tivator® Epstein-Barr virus (EBV) provided by the Miltenyi Biotec Company. Borrelia cells, for example heat-inactivated, may also be mentioned, which may comprise several Borrelia strains such as Borrelia burgdorferi, Borrelia garinii and Borrelia afzelii ((EP2619584A).

According to one embodiment, the method of the invention is such that it implements at least one specific stimulant which is a highly specific antigen for Mycobacterium tuberculosis, which may be absent from the BCG vaccine (Bacille Calmette-Guérin). Preferably, said at least one specific stimulant is selected from ESAT-6, CFP-10 and TB7.7 antigens.

Cytokines are all known cytokines secreted by immune cells such as T cells, for example gamma interferon (IFN-gamma), interleukins (IL), such as IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-16, IL-17, IL-1α, IL-β, IL-1α (IL1RN), chemokines such as CC chemokines, C chemokines, CXC chemokines and CX3C chemokines, tumor necrosis factor a (TNFa), colony stimulating factor (CSF) such as granulocyte (G) -CSF or granulocyte macrophage (GM) -CSF, as well as complement or components of the complement biological pathway, for example C5a, Groa (CXCL1), sICAM-1 (CD54), IP-10 (CXCL10), I-TAC (CXCL1 1), MCP-1 (CCL2), MIF (GIF), MIP-1a (CCL3), MIP-β (CCL4), RANTES (CCL5) and MIG (CXCL9).

According to one embodiment, the cells to be stimulated are cells capable of secreting at least one cytokine.

According to another embodiment, said at least one cytokine that is desired to be secreted is chosen from interleukins, chemokines, tumor necrosis factor-α (TNFα) and interferon-gamma (IFNγ), interferon gamma being a cytokine of choice.

In addition to cytokines, the cells to be grown according to the automated method of the invention may be capable of secreting at least one antibody.

Thus, according to a particular embodiment, the cultured cells are B cells capable of secreting at least one antibody in the presence of at least one nonspecific stimulant or at least one specific stimulant of a pathogenic microorganism.

Non-specific or specific stimulants of a pathogenic microorganism resulting in the production of antibodies are known to those skilled in the art and examples include those previously described for T cells. Other examples include surface antigens of the various pathogens such as HBs antigen for the hepatitis B virus, the surface antigen of the influenza virus, as well as the proteins of an individual generating autoantibodies in him. In general, regardless of the stimulant, this will be the specific antigen of the antibody response obtained. Thus, the antibody that will be secreted will be an antibody directed against these antigenic stimulants.

The biological samples containing the cells capable of secreting the immune effector molecule or molecules that are suitable for the purposes of the invention are any sample containing such cells, such as biological fluids, for example whole blood and its derivatives, the cerebrospinal fluid, the synovial fluid, lachrymal fluid, gingival fluid, urine and saliva. Preferably, the biological sample is a whole blood sample and its derivatives.

The biological samples are not modified before being used in the method of the invention, that is to say that they are used as such following the sampling in the animal organism and that they are not not put in contact with at least one stimulant. Thus, the sample is taken in a container, for example a bottle, containing no stimulant. Likewise, and as indicated above, the biological samples also do not undergo a step of separating or counting the cells. We can then speak of raw sample or sample as sampled or original sample, this sample being not previously brought into contact with at least one stimulant.

The animal organisms from which the biological samples are derived are the persons usually diagnosed or given drugs. They include for example mammals, such as humans, cattle, canines, felines, horses, sheep, goats, pigs, rabbits, reptilians, amphibians, as well as birds such as gallinaceous, or raptors.

According to one embodiment, the biological sample is a sample of human, bovine, canine, feline or equine origin, preferably human.

The first step of the detection or quantification method of the invention comprises the aspiration of a defined quantity of the biological sample as taken by an automated suction / discharge device (step (a)).

Defined quantity means a quantity or a volume of calibrated and always identical sample from one assay to another due to the use of an automated suction / discharge device.

Automated suction / discharge devices are devices widely known to those skilled in the art and are present in a large number of instruments of biochemistry, molecular biology and immunoassay, for example the instruments of the VIDAS® range as VIDAS®, miniVIDAS®, VIDAS® 3 (bioMérieux), Simoa® HD-1 (Quanterix), Cobas® or Elecsys® (Roche Diagnostic GmbH), LIAISON® (Diasorin), Architect® ( Abbott), Access 2 (Beckman Coulter), Clarity ™ (Singulex®), Vitras® (Johnson & Johnson), Centaur® (Siemens), eMAG® and PeasyMAG® (bioMérieux). These automated suction / discharge devices comprise one or more sampling devices for aspirating a liquid medium, such as the biological sample or the reaction media, from the container in which it is located, and then to repress it. They include for example an arm or a support at the end of which is inserted a needle or a tip (tip or cone), which tip is blank or previously coated with connecting partners, such as the SPR® VIDAS® range. As the sampling device is used to suck and then discharge various media, first of all the biological sample, then various reaction media, the tips of said suction / discharge device can be changed and rejected in a bin at various times of the process . Thus, for example, in the context of the VIDAS® instrument, a first tip is used to take the biological sample, then if necessary, another tip is used to bring the said at least one a secretion stimulant, then another bonded partner-coated tip (SPR®) is used to measure the cellular response. When the suction / discharge device comprises several sampling devices, each sampling device has its own role. For example, a first sampling device can be used to aspirate / discharge the biological sample and a second sampling device can be used to aspirate / discharge the necessary reagents for example the incubation and the measurement of the cellular response. The sampling device is guided by a suction / discharge control device, such as for example a device effecting a pressure difference in the sampling device using a piston driven by any means known to the person skilled in the art. such as, for example, using a screw coupled to a motor, forming a pump unit, the sampling device and the suction / discharge control device being connectable via a tubing comprising seals to ensure watertightness. The sampling device and the suction / discharge control device may be more or less distant. The person skilled in the art will adapt the speed and the suction power of the suction / discharge control device according to the quantity of sample that it is desired to take for the stimulation and, if necessary, in function the length and section of the tubing between the suction / discharge control device and the sample container. Thus, for example, in the context of the VIDAS® 3 instrument where the pump unit is close to the cone, the suction speed will be between 10 and 500 μΐ / second.

The sample container is any container adapted to receive a sample: tube, bottle. It can be made of plastic, such as ethylene vinyl acetate (EVA copolymer), polyethylene, polypropylene copolymer, fluorinated ethylene propylene (nalgene), glass or stainless steel. In the case of blood or derivative, the sample container may be a vacuum type blood collection tube, for example a Vacutainer®, Greiner or Terumo tube, for example a heparinized tube, conventionally used to draw blood from a patient.

The sample container or its contents will be placed in the instrument implementing the automated method of the invention before the implementation of this method, by example by an operator or by another automated device.

The quantity / volume of biological sample that will be sucked by said automated suction / discharge device will be easily defined by those skilled in the art according to several parameters such as the instrument that he will use and the nature of the biological sample. In general, the amount of biological sample that will be sucked from the sample container will be between 5 and 800 μί, preferably between 10 and 500 μί. This amount will be at least 10, 15, 20, 25, 30, 35 or 40 μΐ. and at most 100, 150, 200, 250, 300, 350 or 400 μL.

Once the calibrated quantity of biological sample has been sucked up, the latter is then discharged by the same suction / discharge device into a receptacle called receptacle R in which the actual stimulation (incubation) can take place.

As for the sample container, the container R may be plastic, such as ethylene vinyl acetate (EVA copolymer), polyethylene, polypropylene copolymer, fluorinated ethylene propylene (nalgene), glass or stainless steel.

The container R may contain in advance all the components necessary for stimulation, for example, if appropriate, said at least one secretory stimulant, as well as one or more buffers such as phosphate, borate, Tris or HEPES buffers, or else may contain only some of the components, for example if the said at least one secreting stimulant, especially in freeze-dried form (powder, microbeads, capsules, etc.), the other components, present in another container, being made in the container R by the suction / delivery device after discharge of the defined quantity of biological sample for the implementation of the incubation step. Or again the container R may be empty and the components necessary for incubation, present in another container, being brought into the container R by the suction / delivery device after the discharge of the defined quantity of biological sample for the implementation of the incubation step. In particular, said at least one secretory stimulant may be contained in a receptacle E and is introduced into the receptacle R by the suction / discharge device after repressing the defined quantity of biological sample (step (c)). Said at least a secretion stimulant is contained in the container E either in freeze-dried form or in admixture with one or more buffers, as previously described. According to one embodiment, the container R does not contain said at least one secretory stimulant which is contained in a container E.

This container R or E may consist of a single unitary element, for example a bottle, a tube, a box or a well, or it may be included in a set of several containers, such as for example a microtiter plate or a bar containing several wells, such as the bar sold for use in the VIDAS® instrument (bioMérieux, France). In the latter case, the containers R and E may be in the same plate or the same bar.

The container R is sterile or not before the introduction of the defined quantity of biological sample. In any case, it is clean, that is to say that it contains a very small amount of germ. The container R may be covered by a shutter member which will be pierced for the introduction of the defined amount of sample. For example, the container R will be pierced by the suction / discharge device during the delivery step. This also applies to the container E. The shutter member is for example an aluminum foil, a polymer film, a septum or a bonded plastic sheet. The opening of the shutter member may vary from partially to totally, that is to say that the stimulation container R may be fully open or open only on the diameter of the suction / discharge device. For example, if the sampling device contains a pipette tip, which has a conical shape at its end, the suction / discharge device will be programmed by its suction / discharge control device to make the shutter member pierced only by the part comprising the smallest diameter of the tip. Thus, the shutter member can be drilled on a diameter of between 0.5 mm and 5 mm.

Incubation of the defined amount of sample and said at least one stimulant, forming a sample-stimulant mixture, also called a stimulation step, can be performed at a temperature at which the cells are usually found in vivo, i.e. at a temperature close to the average central temperature of the animal organism from which the biological sample is derived, which constitutes a particular embodiment of the invention. Indeed, each organization has a central average temperature of its own. Thus, the average central temperature for a man is 37 ° C, that of cattle 38.6 ° C, that of dogs 38.9 ° C, those of cats 38.6 ° C, that of horses 37, 8 ° C, rabbits 39.5 ° C and chickens 41.7 ° C. For cold-blooded vertebrates, the average central temperature is between 18 ° and 25 ° C. Thus, depending on whether the biological sample comes from one animal organism or another, the temperature to be used in the incubation step of the process of the invention may be different and the skilled person will choose the good temperature depending on the biological sample used and the corresponding average central temperature. Since the cells are able to withstand a variation, the incubation temperature in the process of the invention will preferably be that of the central temperature of the animal organism from which the biological sample + or - 3 ° C, from preferably + or - 2 ° C, or + or - 1 ° C. For example, for humans, the cells will be stimulated at 34 to 40 ° C, preferably at 35 to 39 ° C, or at 36 to 38 ° C, or at 37 ° C. In general, the incubation temperature will be between 18 and 45 ° C, preferably between 35 ° C and 43 ° C. According to one embodiment, the temperature of the incubation step will be at least 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 ° C. The temperature may be at most 38, 39, 40, 41, 42, 43 or 44 ° C.

The duration of the incubation step may vary, in particular as a function of the quantity of cells present in the biological sample, and is generally between 1 h and 72 h. According to one embodiment, the duration of the incubation step is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and 18 h and is at most 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 , 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 54, 57, 60, 63, 66, 69, 70 or 71 h. Preferably, the duration of the incubation step is between 2 and 24 hours, and more preferably between 6 and 18 hours.

The incubation may take place (i) in said container R, which is preferred, or (ii) in another container S after suctioning and discharging said mixture by means of said automated suction / discharge device.

It is conventionally known to proceed to the cell incubation step Immune, contained in the biological sample or separated, as in Elispot, with the secretory stimulant (s) in sterile condition. However, the Applicant has shown that this condition is not necessary. Also, the container R does not need to be placed in a sterile condition during the cell incubation step. Thus, according to one embodiment, the container R is non-sterile after introduction of the defined amount of sample and / or the incubation step (d) takes place in a non-sterile condition, which is quite unexpected.

If the implementation of an incubation step under sterile conditions requires a particular device to meet this condition, such as the laminar flow hood or the vacuum blood collection tube, the implementation of a step of Incubation in non-sterile conditions is particularly easy in that it does not require any particular device. Thus, any instrument of biochemistry, molecular biology or immunoassay comprising an automated suction / discharge device as described above is suitable for such an incubation step in non-sterile condition.

The last step of the method of the invention consists in detecting the immune cell response which is specific for the at least one secretory stimulant, and this directly from the sample-stimulant mixture since, contrary to all expectations, no centrifugation of the cells is possible. necessary before the detection of this immune cellular response. By specificity of said at least one secretory stimulant is meant that the use of another stimulant with the same type of cell (B or T) could give a different response, for example other antibodies or other cytokines.

The detection of the immune cell response can be carried out by any method known to those skilled in the art, such as by immunoassay, by proliferation assay, by measuring the level of expression of the RNA transcripts according to known methods in molecular biology or by flow cytometry. It will or will implement at least one binding partner to the immune effector molecule or its corresponding RNA transcript, which comprises any partner capable of binding to said molecule or said transcript. The nature of the binding partner will depend on the nature of the analyte and the type of test used. Preferably, the test will be an immunoassay or a molecular biology test. Of course, the term "immuno" in "immunoassay" for example, is not to be considered in this application as strictly indicating that the binding partner is an immunological partner, such as an antibody. Indeed, those skilled in the art also use this term widely when the binding partner, also called ligand, is not an immunological partner but is for example a receptor for the analyte that is to be assayed. Thus, it is known to speak of the ELISA ("Enzyme-Linked Immunosorbent Assay" literally "bound enzyme immunoadsorption assay") for assays that use non-immunological binding partners, more broadly called in English "Ligand Binding Assay" Which could be translated as "Ligand binding assay", while the term "immuno" is included in the acronym ELISA. For the sake of clarity, the Applicant will use throughout the application the term "immuno" for any test or assay using a binding partner, even when it is not an immunological partner.

If step (e) implements at least one at least one binding partner for the immune effector molecule, it may comprise the steps of:

(e ') contacting said secreted immune effector molecule with at least one binding partner to said molecule and

(f) revealing the presence or amount of molecule by its binding to said at least one binding partner.

By way of examples of immunoassay binding partner, mention may be made of binding partners of nature or of immunological origin such as antibodies (monoclonal or polyclonal) and antibody fragments (such as Fab, Fab ', F (ab ') 2), chains scFv (Single chain fragment variable), dsFv (Double-stranded variable fragment)), well known to those skilled in the art, as well as the binding partners not being of nature or immunological origin, such as proteins other than antibodies, peptides, oligonucleotides, nanofitins, receptors with the molecule of interest if they exist, aptamers, DARPins or any other molecule that is known to interact with said molecule of interest.

Nanofitins (trade name) are small proteins that, like antibodies, are able to bind to a biological target, allowing it to be detected. to capture it or just target it within an organism.

Aptamers are oligonucleotides, generally RNA or DNA, identified in libraries containing up to 1015 different sequences, by an in vitro selection combinatorial method called SELEX for "Systematic Evolution of Ligands by Exponential Enrichment" (Ellington AD and Szostak JW. , 1990). Most aptamers are composed of RNA, because of the ability of RNA to adopt varied and complex structures, which allows to create on its surface cavities of varied geometries, allowing to fix various ligands. These are biochemical tools of interest that can be used in biotechnological, diagnostic or therapeutic applications. Their selectivity and ligand binding properties are comparable to those of antibodies.

"DARPins" for Designed Ankyrin Repeat ProteINS (Boersma YL and Plutckthun A, 2011) are another class of proteins that mimic antibodies and can bind with high affinity and selectivity to target proteins. They derive from the family of ankyrin proteins that are adapter proteins that make it possible to bind integral membrane proteins to the spectrin / actin network that constitutes the "spine" of the cellular plasma membrane. The structure of the ankyrins is based on the repetition of a pattern of about 33 amino acids and so are the DARPins. Each pattern has a secondary structure of the helix-turn-helix type. The DARPins contain at least three, preferably four to five repeating units and are obtained by "screening" combinatorial libraries.

Examples of binding partners include anti-IFN-gamma antibodies, anti-antibody antibodies, pathogen proteins or fragments thereof (e.g., HCV NS3 protein, HBsAg HBV, etc.) and phage proteins, which are widely known to those skilled in the art and commercially available.

The contacting of the secreted immune effector molecule and said at least one binding partner is carried out in a receptacle different from the receptacle R or in the receptacle R. In the latter case, the binding partner is previously contained in the receptacle. container R or it will be provided later by the suction / discharge device. If the contacting of the immune effector molecule secreted and said at least one binding partner is implemented in a different container of the container R, for example in a container T, according to one embodiment, it is the contents of the container R which will be sucked and then pushed back into the container T using the suction / discharge device. Here again, the binding partner may be contained in the container T beforehand, or it will be provided later by the suction / discharge device. Said at least one binding partner can be either immobilized on the surface of the containers (R or T), or it can be present in freeze-dried form. According to another embodiment, the bonding partner is immobilized on the surface of a tip used with the suction / discharge device, for example in the context of kits implemented with the VIDAS® instrument (SPR® cone). ). The application of such a partner on the surface of a container or tip is widely known to those skilled in the art.

Immunoassay methods are widely known to those skilled in the art and include, for example, enzyme immunoassays or EIA for Enzyme Linked Immunoassay. These are coupled to an enzyme catalyzed reaction using an enzyme substrate. Depending on the enzymatic substrate chosen, one can have a colorimetric signal (ELISA for Enzyme-Linked Immunosorbent Assay) (Rassasie, MJ, et al, 1992), a fluorescence signal (ELFA technology for Enzyme Linked Fluorescent Assay) or a chemiluminescent signal ( CLIA for Chemiluminescence Immuno Assays) (Stabler TV, et al., 1991).

The detection of the immune cell response can be qualitative, semi-quantitative or quantitative. In the context of immunoassays, it is based on measurements making it possible to quantify the signals emitted during the analysis of the biological sample containing the molecule of interest. The quantity of signals detected is generally proportional to the quantity of molecule of interest to be measured (for example during a sandwich type test, using two binding partners) or inversely proportional to the quantity of analyte to be measured (for example in a competitive trial, using a single binding partner and a compound that competes with the molecule of interest).

Typical steps for a sandwich immunoassay in a biological sample, also called a test sample, which may contain said analyte or molecule of interest, comprise or consist of:

the placing in the presence of said at least one binding partner and said test sample likely to contain the molecule of interest for fixing the molecule of interest on the binding partner,

the addition of a detection partner, which is coupled directly or indirectly to a marker, such as an enzyme capable of lysing an enzymatic substrate, for example fluorogenic for an ELFA detection, for its attachment to the binding partner complex -molecule of interest,

when the marker is an enzyme, bringing into the presence of an enzymatic substrate and the binding partner-molecule complex of interest-detection partner coupled to an enzyme for the formation of a reaction medium, and

the detection, for example by immunofluorescence in the context of an ELFA detection, of the presence and / or the quantity of molecule of interest by measuring the signal (for example fluorescence) emitted in the reaction medium.

By detection partner is meant any partner capable of binding to the molecule of interest to detect or quantify, which will be coupled directly or indirectly to a marker, for example an enzyme. It may be of the same nature as the liaison partner or of a different nature. Examples are given previously with the link partner.

By direct or indirect coupling of the marker to the detection partner, it is meant that the marker is attached directly to the detection partner recognizing the analyte (direct coupling) or the enzyme is coupled to a binding partner which recognizes the partner detecting the analyte itself (indirect coupling).

Thus, in the context of direct coupling, the complex formed at the end of the assay, called the conjugate, will consist of: "binding partner / molecule of interest / detection partner coupled to the marker".

In the context of indirect coupling, the complex formed at the end of the assay will consist of: "binding partner / molecule of interest / detection partner / binding partner coupled to the marker". By marker is meant, in particular, any molecule containing a group reactive with a group of the detection partner, directly without chemical modification, or after chemical modification to include such a group, which molecule is capable of directly or indirectly generating a detectable signal. A non-limiting list of these direct detection markers consists of:

enzymes which produce a detectable signal for example by colorimetry, fluorescence, luminescence, such as horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose-6-phosphate dehydrogenase,

chromophores such as fluorescent compounds, luminescent compounds, dyes,

32 35 125

"Radioactive molecules such as ^J , ^JJ S or ^1ZJ I,

fluorescent molecules such as Alexa or phycocyanins, and electrochemiluminescent salts such as organometallic derivatives based on acridinium or ruthenium.

Of course, the binding partner may itself be marked as indicated above. As part of a sandwich test, the second partner used will not be marked.

Thus, according to one embodiment, the detection method of the invention is characterized in that step (e) implements a binding partner to the immune effector molecule which is an immunoassay partner and in that the revelation of the binding or not of said molecule is carried out by a sandwich type test using another molecule binding partner, of different or different nature, one of the two partners being marked.

Conventional steps for a competition-type immunoassay in a test sample that may contain said molecule of interest include:

placing said at least one binding partner, an analogue to the molecule of interest coupled to a marker, for example an enzyme capable of lysing an enzymatic substrate, for example a fluorogenic substrate, and said sample, which enter into competition for fixation on the liaison partner,

when the marker is an enzyme, bringing into the presence of an enzymatic substrate, binding partner-molecule of interest complexes and binding partner-analogous to the molecule of interest for the formation of a reaction medium, and the detection, for example by immunofluorescence, of the presence and / or amount of analyte by measuring the signal, for example the fluorescence, emitted in the reaction medium.

Analogous to the analyte is any molecule which has the same binding capacity to the binding partner as the molecule of interest.

The marker coupled to the analog of the molecule of interest is equivalent to the marker useful in the context of a sandwich test.

According to another particular embodiment of the invention, the detection method of the invention is characterized in that step (e) implements a binding partner to the immune effector molecule which is an immunoassay partner. and in that the revelation of the binding or not of said molecule is carried out by a competitive test using a labeled compound competing with the molecule of interest.

Whatever the type of method used, sandwich or competitive type, the enzyme is a widely appropriate marker and can be mentioned in particular as an example sulfatase, peroxidase, alkaline phosphatase (PAL), acid phosphatase, glucose oxidase (GOx), glucose-6-phosphate dehydrogenase (G6PD) and β-galactosidase (β-gal). The corresponding enzyme substrates are widely known to those skilled in the art and include, for example, 4-methylumbelliferyl phosphate or 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside.

According to a particular embodiment, in the detection method according to the invention, the revelation of the analyte is carried out using an enzyme and an enzymatic substrate catalyzed by said enzyme, preferably alkaline phosphatase and 4-methylumbelliferyl. phosphate.

When the immune cell response is obtained by detection of the RNA transcript of the gene of the immune effector molecule, also called target gene, the measurement of its level of expression implements RNA detection methods well known to the patient. skilled in the art, using conventional instruments such as Filmarray® (bioMérieux), LightCyclerl .O, 2.0 and 480 (System II), Applied Biosystems 7500, 7500 Fast, 7500 Fast Dx, 7300, ViiA ™ 7 Real -Time PCR System, StepOne, Rotor-Gene, Real-Time System Dx and CFX 96 Real-Time System. Thus, these methods can firstly include a preliminary step of extracting the total RNAs from the biological sample (ribosomal RNA, transfer RNA and messenger RNA). This step is followed by a reverse transcription step of these different RNAs in order to obtain their complementary DNA (cDNA). Then the specific cDNAs of the target gene are amplified, detected and then quantified.

The extraction is carried out by all nucleic acid extraction and purification protocols well known to those skilled in the art. By way of indication, the extraction of nucleic acids can be carried out by lysis of the cells present in the biological sample followed by purification, for example on magnetic beads, or by extraction with phenol, chloroform and magnesium. 'alcohol. These steps are well known to those skilled in the art and are described for example in patents US5234809, EP0245945, WO93 / 01312, WO00 / 21973, WO02 / 16383 or in the technical manuals of sample preparation kits and platforms (sample prep) MagNa Pure, QiaCube, EasyMAG®, QiaAmp DNA mini Kit.

A reverse transcription reaction is then carried out using a reverse transcriptase enzyme which makes it possible to obtain, from an RNA fragment, a complementary DNA fragment (cDNA). The realization of such a step is well known to those skilled in the art (general review, 2003). When it is more particularly desired to obtain the complementary DNAs of the messenger RNAs, this enzymatic step is carried out in the presence of nucleotide fragments comprising only thymine bases (polyT), which hybridize by complementarity on the polyA sequence of the different mRNAs in order to forming a polyT-polyA complex which then serves as a starting point for the reverse transcription reaction carried out by the enzyme reverse transcriptase. We then obtain different DNA complementary to the different messenger RNAs initially present in the biological sample.

Then, in order to specifically amplify the specific cDNAs of the target gene, an enzymatic amplification reaction is performed. An enzymatic amplification reaction is a process that generates multiple copies of a nucleotide fragment by the action of at least one enzyme. Such amplification reactions are well known to those skilled in the art and may be mentioned in particular the following techniques: PCR (Polymerase Chain Reaction), as described in patents US4683195, US4683202 and US4800159, and all its variants;

LCR (Ligase Chain Reaction), for example disclosed in patent application EP 0201184;

- RCR (Repair Chain Reaction), described in the patent application

WO90 / 01069;

3SR (Self Sustained Sequence Replication) with patent application WO90 / 06995;

NASBA (Nucleic Acid Sequence-Based Amplification) with the patent application WO91 / 02818;

- TMA (Transcription Mediated Amplification) with the patent US5399491;

- LAMP (Loop mediated isothermal amplification) with the patent US6410278;

SDA (Strand Displacement Amplification) described in Y. Masamute and C. C. Richardson, 1971, J. Biol. Chem. 246, 2692-2701; R.L. Lechner et al., 1983, J. Biol. Chem. 258, 11174-11184; or R.C. Lundquist and B.M. Olivera, 1982, Cell 31, 53-60;

- CRCA (cascade rolling circle amplification);

ICAN (isothermal and chimeric primer-initiated amplification of nucleic acids) described in T Uemori, 2007, J Biochem. 2007 Aug; 142 (2): 283-92;

- HDA (target based helicase-dependent amplification) described in Vincent et al, 2004, Embo reports, 5 (8): 795-800.

We then speak of amplicons to designate the polynucleotides generated by an enzymatic amplification technique. Preferably, when the enzymatic amplification is a PCR, the specific reagent comprises at least 2 specific amplification primers in order to amplify a particular region of the DNA complementary to the mRNA derived from the target gene. When the enzymatic amplification is a PCR carried out after a reverse transcription reaction, it is called RT-PCR. Among the variants of the PCR, mention may in particular be made of the nested polymerase chain reaction or nested PCR (Nested-PCR) which involves two PCR amplifications thanks to the presence of two successive PCRs and two different pairs of primers: the first pair of primers is used for the first PCR (classical PCR), the second pair of primers serving during the second PCR and being defined in such a way that it hybridizes to a sequence present in the amplification product (amplicon) of the first PCR.

Following this amplification step, whatever the technique used, the level of expression of the target gene is determined for example by hybridization using at least one hybridization probe specific for the expression product of this gene. target gene, which corresponds to the RNA transcript binding partner of interest, or using an intercalator of double-stranded DNA such as SybrGreen®.

By hybridization probe is meant a nucleotide fragment comprising from 5 to 100 nucleotide units, in particular from 6 to 35 nucleotide units, having hybridization specificity under determined conditions to form a hybridization complex with a target nucleotide fragment. In the present invention, the target nucleotide fragment may be a nucleotide sequence comprised in a

Messenger RNA or a nucleotide sequence included in a complementary DNA obtained by reverse transcription of said messenger RNA.

Hybridization techniques are well known to those skilled in the art, and mention may in particular be made of the Northern blot technique.

The quantification of the mRNAs, expression products of the target gene, goes through a step of detecting the hybridization reaction, between the hybridization probe or the intercalator of the DNA and the target nucleotide fragment.

Detection means either direct detection by a physical method or a detection method using a marker. Many detection methods exist for the detection of nucleic acids (Keller CH., 1993; Kricka,

1999).

Those skilled in the art will be able to refer in particular to the publications of Bustin SA and Giulietti A et al. (Bustin SA, 2002, Giulietti A, 2001).

All that has been previously described about immunoassays in the different process steps and the use of a binding partner can be applied to molecular biology detection.

The detection method of the invention may also comprise one or more additional rinsing steps after each step, for example: before the addition of the detection partner, a rinsing step so as to eliminate the molecule unrelated to the binding partner-molecule of interest complex; and

after the addition of the detection partner, a rinsing step so as to eliminate the unbound detection partner.

The rinsing steps are steps known to those skilled in the art. They are implemented with buffers compatible with the reaction medium and the reading of the signal.

Steps (a) to (d) are of course implemented before step (e), but several embodiments are possible. Thus, the detection method of the invention comprises one or more of the following characteristics:

steps (a) to (e) are implemented with the same instrument;

steps (a) to (e) are implemented successively in the same day;

the steps (a) to (d) are implemented on a first day or for several days, for example up to 3 days, as defined above, and the step (e) is implemented then another day, for example 1, 2 or 3 days later.

By the same instrument is meant the same instrument to perform all the steps successively, or two instruments of the same range, one to bring into contact the at least one stimulant and the biological sample as sampled, and the other to detect the immune cell response. Thus, thanks to the use of the same instrument, the method is completely automated by using simplified equipment that does not require the presence of a highly qualified staff, or the implementation of very specific conditions when the incubation step is implemented in non-sterile condition. In this particular embodiment, the suction / discharge device may be used to transfer the biological sample containing the secreted molecule of interest to the container or containers used for step (e), as indicated above. The one or more containers necessary for the implementation of all the steps of the method of the invention may be put into the instrument before step (a) or they can be put in two stages, depending on the phase (stimulation / detection). Examples of instruments that can be used include any diagnostic instruments already commercially available, for example, immunoassay or molecular biology, which include:

A suction / discharge device for taking the biological sample from a patient and putting it in a container for stimulation, and then for the detection of the immune cell response, A set of containers to be able to perform the stimulation and the detection,

Optionally a system for maintaining the temperature of the container used for incubation at the chosen temperature and

A system for detecting the immune cell response.

Non-limiting examples of suitable immunoassay instruments include instruments of the VIDAS® range such as VIDAS®, miniVIDAS®, VIDAS® 3 (bioMerieux), Simoa® HD-1 (Quanterix), Cobas® or Elecsys® (Roche Diagnostic Gmbh), LIAISON® (Diasorin), Architect® (Abbott), Access 2 (Beckman Coulter), Clarity ™ (Singulex®) and Vitras® (Johnson & Johnson).

For example, the instrument of the VIDAS® range (bioMérieux) uses a suction / discharge device consisting of a cone (SPR®) on a support, which cone is coated with a connecting partner, a bar comprising 10 wells (thus 10 containers) including a sample well, a well for stimulation, a well for reading the signal representative of the detection of the immune effector molecule and wells that may contain the various constituents, for example those necessary for stimulation and the immunoassay used for the detection of the immune cell culture. This instrument also has a system for regulating the temperature of the wells of the bar. The VIDAS® 3 instrument also has an arm with a tip.

As indicated above, the method for detecting the immune cell response of the invention can be divided into two phases, the first phase of which constitutes another subject of the invention, which is an automated method for stimulating at least one cell capable of secreting an immune effector molecule for the secretion of said molecule, said at least one cell being derived from a biological sample of animal origin, characterized in that it comprises or consists of the steps of:

The characteristics related to the biological sample, the cells to be cultured, the immune effector molecule, also called molecule of interest or analyte, the diseases of interest, the stimulation / incubation conditions, with or without stimulant (s) specific pathogen (s), the automation devices used, the methods of detection of the immune response, etc., as described previously in the context of the detection method of the invention also apply for the stimulation method .

The molecule thus obtained by automated stimulation and its detection are particularly useful in the medical field. Also the invention also relates to the use of the method for detecting an immune cell response or the automatic stimulation method as described above for the diagnosis and monitoring of pathologies, for toxicity studies of drugs and vaccines and for determining the immune status of a patient.

The pathologies concerned have been described previously. At the same time, it is It is important that drugs and vaccines, future or otherwise, are non-toxic and the methods of the invention can be used to this end. Finally, since the immune status of a patient is evaluated via the ability of the cells involved in the immune response to secrete immune effector molecules, the method of the invention is particularly well suited for this purpose.

The invention will be better understood with the aid of the following examples which are given by way of non-limiting illustration, and also with reference to FIG. 1 which is a diagrammatic representation of the cone and the bar used with the instrument. VIDAS®, the cone belonging to the suction / delivery device to aspirate and repress the defined amount of biological sample in a stimulation well.

EXAMPLES

Example 1: Automation of the stimulation step, collection of whole blood, stimulation with a nonspecific stimulant, gamma interferon assay

1.1. Implementation of the secretion step

The blood samples used in this example were obtained from French Blood Establishments (EFS) and collected from healthy donors. Five blood samples were collected in sterile Vacutainer® (Becton-Dickinson) tubes containing lithium heparin or equivalent reference from another supplier.

These samples were stimulated under two conditions (1 and 2)

Condition 1: Stimulation tube, according to the prior art - sterile conditions of stimulation. Sterile dry tubes (Cat No. 367614, Becton-Dickinson) are used for this condition. In sterile conditions, under a laminar flow hood, each blood sample is stimulated in 3 different ways:

Test 1: PBS tube (negative control): 400 of PBS buffer are mixed with 400 of whole blood.

Test 2: phorbol 12-myristate 13 -acetate (PMA) phytohemagglutinin (PHA) tube: 400 of stimulants PMA (2.30 ng / ml) and PHA (0.46 μg / ml) are mixed with 400 μl of blood total. Test 3: Phorbol 12-myristate 13 -acetate (PMA) phytohemagglutinin (PHA) tube: 400 μl. PMA stimulants (25 ng / ml) and PHA (5 μg / ml) are mixed with 400 μl of whole blood.

The tubes were capped under hood and then incubated vertically at 37 ° C for 17h30 hours.

Condition 2: Automated Stimulation in VIDAS® Cartridge - Non Sterile Stimulation Conditions. The bar of the VIDAS® immunoassay automaton is depicted in FIG. 1. The latter (11) is composed of 10 wells (1 to 10) partially covered with a labeled sealed aluminum foil (not shown). The last well (10) is an optical cuvette in which the fluorescence is measured and contains the enzymatic substrate. The different reagents necessary for stimulation and / or analysis as the stimulant (here PBS well or PMA-PHA well), the washing solutions or the revealing antibody, are contained in the various other wells (1-9). .

The strips thus prepared were inserted into the VIDAS® 3 automaton and the whole blood tubes taken from the donors. Before loading the tubes into the PLC, their plug is removed. From that moment on, the whole blood samples are no longer treated in sterile conditions. The VIDAS® 3 instrument has been programmed to automatically perform the following steps:

1) Aspirate by the suction / discharge device a precise volume of whole blood (400 μί) from the primary sampling tube

2) Drill the aluminum foil covering the stimulation well using the suction / discharge device,

3) Refold the whole blood in the stimulation well

4) Incubate the cartridge at 37 ° C for 17h30.

Following this stimulation step, VIDAS® 3 can automatically follow with the step of detection of ΓΙΚΝγ secreted, according to the procedure described below in section 1.2.

The stimulation conditions in sterile tube (tube) or in the bar

VIDAS® (wells) are summarized in Table 1 below. Table 1: Stimulation conditions in sterile tube or in automaton wells

PMA: phorbol 12-myristate 13 -acetate

PHA: phytohemagglutinin

1.2. IFNy detection step: mode of operation of the automated immunoassay Detection principle

The detection of ΓΙΚΝγ in the biological samples is carried out by one-step sandwich immunoassay using the VIDAS® immunoassay automaton (bioMérieux). The disposable cone (shown at 12 in Figure 1) serves both as a solid phase for the reaction and as a pipetting system. It is used in combination with the bar (11), as described in point 1.1 above. All the test steps are thus automatically performed by the instrument. They consist of a succession of suction / discharge cycles of the reaction medium.

Sensitization and passivation of cones. The cones were sensitized with 270 μl of a solution of a first anti-IFNγ monoclonal antibody (4G1E12, bioMérieux, France) at 5 μιηηΐ in a carbonate buffer. After about 6-8h of incubation at + 18/25 ° C with the sensitizing solution, the cones were emptied. Then, 300 μl of phosphate buffer containing 10 g / l of bovine albumin are added for the passivation of the cones at + 18/25 ° C. for about 18-24 hours. The cones are then emptied, dried and stored at + 4 ° C until use, protected from moisture. Preparation of Conjugated Antibody Solutions The conjugate solution (detection partner) contains a second anti-IFNγ monoclonal antibody coupled to alkaline phosphatase (2A4B11, bioMérieux). Conjugated antibodies were diluted to about 500 ng / ml in Phosphate / BSA buffer.

Immunoassay. As soon as the VIDAS® cone is in contact with the sample, the immunological reaction begins because the capture antibodies are immobilized on this cone. Mixing the test sample controller (100 μΐ _^ - in this case the blood after stimulation) with 250 of conjugate solution. The incubation lasts approximately 10 minutes at 37 ° C. and allows the specific binding of γγ to the antibody adsorbed on the cone on the one hand (capture antibody) and on the conjugated antibody (detection antibody) on the other hand . Then, the unbound components are removed by 3 washes with Tris NaCl buffer. During the final revelation step, the 4-methylumbelliferyl phosphate substrate is sucked and then forced back into the cone; the conjugated antibody enzyme catalyzes the hydrolysis reaction of this substrate to 4-methylombelliferone whose emitted fluorescence is measured at 450 nm. The value of the fluorescence signal (RFV) is proportional to the concentration of the antigen present in the sample.

The results of the assays are presented in Table 2:

Table 2: Measurement of IFNy by VIDAS

IFNy measurement by VIDAS

RFV signal

Ratio Ratio

Containing PMA / PHA PMA / PHA

PMA-PHA PMA-PHA code of PBS concentration concentration

sample concentration concentration strong stimulation weak

strong / PBS low / PBS

Tube 23 11447 229 498 10

0312274

Well 11 11516 72 1047 7

Tube 15 11319 111 755 7

0312370

Well 8 10928 48 1366 6

Tube 26 11216 767 431 30

0312397

Well 16 13588 543 43.6 34

Tube 16 11306 610 707 38

0312303

Well 7 8905 172 1272 25 Very high secretion of INFy (signals> 8000 RFV) is observed when the cells are stimulated using a high concentration of PHA in the PMA / PHA mixture while the secretion is moderate (<800 RFV signals) if the concentration of PHA is low in the PMA / PHA mixture. This phenomenon is observed both for the stimulation performed in the tube and for that carried out in the well.

Non-specific secretion in the absence of stimulant (PBS test) is very weak in tube (<30 RFV signals) and almost non-existent in the well (<20 RFV signals).

The level of secretion of INFy obtained after stimulation is compared with that measured in the absence of stimulant by calculating a ratio between the two measurements. If the ratio is at least 3, we conclude positively.

When the stimulation is carried out in the well, the ratios vary from 6 to 1366 whereas, when the stimulation is carried out in the tube, the ratios vary from 7 to 755. It can thus be concluded that the stimulation causing the secretion of INFy is equivalent or better in the well than in the tube.

Example 2: Automation of the stimulation step, collection of whole blood, stimulation with a specific stimulant (Mycobacterium tuberculosis antigens), gamma interferon assay

The blood samples used in this example were obtained from

Biotech Bank (Angers, France) and collected either from people who have had tuberculosis or are close to them. Four blood samples were collected sterile in Vacutainer® tubes (Becton-Dickinson) containing lithium heparin or equivalent reference from another supplier.

Each blood sample was stimulated according to 3 different protocols detailed in Table 3 below, using as a stimulating agent the contents of the Quantiferon® TB tubes (Cat No. T0590-0301, Qiagen). Quantiferon® TB tubes are special vacuum blood collection tubes that allow the collection of whole blood under perfectly sterile conditions. There are 3 of them:

The AG tube, for antigen, contains peptides derived from ESAT-6 proteins,

CFP-10 and TB7.7 of Mycobacterium tuberculosis; this is the tube for stimulation specific. If there is secretion of IFNy in this tube, it is because the sample contains T cells that are able to react specifically against M. tuberculosis peptides.

The NIL tube corresponds to the negative control and the MIT tube, which contains a mitogen, corresponds to the positive control.

Each sample was stimulated by the contents of the 2 tubes AG and NIL Quantiferon and according to 2 protocols, which corresponds to a total of 4 conditions per sample.

In routine use, according to the manufacturer's instructions, 0.8 to 1.2 mL of whole blood is collected directly from the Quantiferon® TB tubes in a sterile manner and the stimulation phase is sterile in the pre-filled tubes. secretory stimulants. Then, the samples thus stimulated are centrifuged and the detection of interferon gamma is carried out in a microplate in the plasma thus obtained. However, in order to be able to compare with the automated stimulation, we slightly modified this procedure, as shown in Table 3:

Table 3: Conditions of stimulation and detection of interferon gamma

The detection of IFNy in the blood samples after stimulation was carried out according to the procedure detailed in paragraph 1.2 of Example 1. The results (RFV signal measured by VIDAS®) according to the experimental conditions) are given in Table 4 below:

Table 4: Measurement of IFNy by VIDAS

Results: The protocol for stimulation and detection of the automated immune cell response, without centrifugation and in non-sterile conditions, makes it possible to obtain signals (11-1954 RFV) equivalent to or greater than those obtained with the sterile tube reference protocol ( 14-1083 RFV). The AG / NIL ratio ranges from 1.1 to 43.6 for the automated condition and from 1.1 to 17.1 for the reference condition, reflecting an equivalent or greater specific stimulation in the automated condition.

Samples BK-37, BK-38, BK-33 and BK-34 have AG / NIL ratios which vary between 1.0 and 2.8 under the two conditions tested. The level of secretion detected IFNy is basal (ratio <3) and is not specific for M. tuberculosis antigens. Therefore the automated condition and the reference condition allow to conclude that these patients were not infected with M. tuberculosis: negative interpretation (Neg).

The BK-40 sample has AG / NIL ratios between 4.2 and 5.3 according to the stimulation protocol, highly concordant. In this sample, a secretion of IFNy (ratio> 3) triggered specifically by M. tuberculosis antigens is observed. We can conclude that patient BK-40 has already been infected with M. tuberculosis: positive interpretation (Pos). The same interpretation is obtained for samples BK-39 and BK-20 for which the highest levels of specific secretion of IFNy are highlighted. For these patients, the AG / NIL ratios are not equivalent between the 2 conditions: ratios of 43.6 and 17.1 are respectively observed for the automated condition against 9.1 and 6.1 for the reference condition, which shows an improved analytical sensitivity for the automated condition, without centrifugation step and in non-sterile condition with a calibrated amount of blood, compared to the reference condition (sterile conditions with varying amount of blood).

Example 3: Automation of the stimulation step, collection of whole blood, nonspecific stimulation PMA + PHA, TNF alpha assay

3.1. Implementation of the secretion step

The blood samples used in this example were obtained from French Blood Establishments (EFS) and collected from healthy donors. 2 blood samples were collected in Vacutainer® tubes (Becton-Dickinson) containing lithium heparin or equivalent reference from another supplier and stimulated either in tube (sterile reference condition) or in VIDAS® wells (according to the invention) according to the procedure described in section 1.1.

The conditions of stimulation in sterile tube (tube) or in the bar of VIDAS® (well) are summarized in Table 5 below:

Table 5: Stimulation conditions in sterile tube or in automaton wells

containing

Conditions Stimulating secretion

stimulation

PB S Tube PB S (Negative Control)

PMA-PHA Strong concentration PMA tube 25 ng / ml + PHA 5 μ ^ ιηΐ in PB S

PB S Well PB S (Negative Control)

PMA-PHA Strong concentration Well PMA 25 ng / ml + PHA 5 μ ^ ιηΐ in PB S At the end of the stimulation step, the sample is taken in order to measure the concentration of TNFα with the kit of Quantikine® HS ELISA human TNFa immunoassay of R & D Systems (Cat No. HSTA00D) by applying the procedure recommended by the manufacturer (manual version 12/13).

3.2. Results of the TNF alpha assay

The experimental results obtained are presented in Table 6 below:

Table 6: TNFa measurement by ELISA

As shown in Table 6, very high TNFα secretion (concentration greater than 32 μg / mL) is observed when the cells are stimulated using a high concentration of PHA in the PMA / PHA mixture. This phenomenon is observed both for the stimulation performed in the tube and for that carried out in the well. Nonspecific secretion in the absence of stimulant (PBS test) is very weak both in the tube and in the well (concentration <3 μg / mL).

When the stimulation is performed in the well, the ratios are 10.8 and 33, comparable to those calculated when the stimulation is performed in the tube, respectively 14.9 and 24.1. It can therefore be concluded that the secretion of TNFα was stimulated by the PMA-PHA mixture equivalently in the tube and the well. Example 4: Automation of the stimulation step, whole blood sampling, non-specific LPS stimulation, TNF alpha assay

4.1. Implementation of the secretion step

The blood samples used in this example were obtained from French Blood Establishments (EFS) and collected from healthy donors. 2 blood samples were collected in Vacutainer® tubes (Becton-Dickinson) containing lithium heparin or equivalent reference from another supplier.

The samples were stimulated either in tube (REF sterile condition) or in VIDAS® wells (according to the invention), according to the procedure described in paragraph 1.1 of Example 1, with the difference that the PMA + mixture PHA was replaced with a 50/50 mixture of E. coli lipopolysaccharides (LPS, Sigma, Cat No. L3012, L2637 and L3137). The stimulation conditions are summarized in Table 7:

Table 7: Stimulation conditions in sterile tube or in automaton wells

At the end of the stimulation step, the sample is taken to measure the TNF alpha concentration with the R & D Systems Quantikine® HS ELISA human TNF alpha immunoassay kit (Cat No. HSTA00D) using the recommended procedure. by the manufacturer (manual version 12/13).

4.2. Results of the TNF alpha assay

The experimental results obtained are shown in Table 8: Table 8: TNFa measurement by ELISA

As shown in Table 8, a very high TNFα secretion (concentration> 32 μg / mL) is observed when the cells are stimulated using LPS. This phenomenon is observed both for the stimulation performed in the tube and for that carried out in the well.

Nonspecific secretion in the absence of stimulant (PBS test) is very weak both in the tube and in the well (concentration <3 μg / mL).

When the stimulation is performed in the well, the ratios are 10.8 and 33 comparable to those calculated when the stimulation is performed in the tube, respectively 14.9 and 24.1. It can therefore be concluded that the secretion of TNFα was stimulated by LPS equivalently in the tube and the well.

Example 5: Automation of the stimulation step, collection of whole blood, stimulation with a specific stimulant (Cytomesalovirus antigens), interferon gamma assay

The blood samples used in this example were obtained from the French Blood Establishment (EFS Rhône-Alpes, France). Thirteen blood samples were collected in sterile Vacutainer® tubes (Becton-Dickinson) containing lithium heparin or equivalent reference from another supplier.

Each blood sample was stimulated according to the "Automated Condition According to the Invention" protocol described in Table 3 of Example 2 using the content of the Quantiferon® CMV tubes (Cat No. 0192-0301) as stimulatory agent. , Qiagen). Quantiferon® CMV tubes are blood collection tubes under vacuum, particular, which allow the collection of whole blood in perfectly sterile conditions. There are 3 of them:

The AG tube, for antigen, contains peptides of Cytomegalovirus; it is the tube for specific stimulation. If IFNy secretion occurs during this stimulation, it is because the blood sample contains T cells that are capable of specifically reacting against the peptides of Cytomegalovirus.

Each sample was stimulated by the contents of AG and NIL Quantiferon tubes.

The detection of IFNy in the blood samples after stimulation was carried out according to the procedure detailed in paragraph 1.2 of Example 1.

The results (RFV signal measured by VIDAS®) according to the experimental conditions) are given in Table 9 below.

Table 9: measurement of IFN γ by VIDAS®

Results: The stimulation and detection protocol of the automated immune cell response, without centrifugation and in non-sterile conditions, makes it possible to obtain signals from 3 to 12053 RFV and AG / NIL ratios varying from 0.9 to 1339.

Samples 59180446129, 59180447383, 59180447498, 59180447500, 5918040405-, 59180404113, 59174894208, and 59174890020 have AG / NIL ratios that range from 0.9 to 3.9. The level of secretion detected IFNy is basal (ratio <5) and is not induced by the peptides of Cytomegalovirus. Therefore, the stimulation in automated condition makes it possible to conclude that these patients have not been infected with Cytomegalovirus: negative interpretation (Neg).

Samples 59180404025, 59180404324, 59180404076, 59174894224 and 59174890039 show AG / NIL ratios between 17.2 and 1339. In these samples, a secretion of IFNy (ratio> 5) triggered specifically by the peptides of the Cytomegalovirus is observed. Therefore, stimulation in automated condition leads to the conclusion that these patients were infected with Cytomegalovirus: positive interpretation (Pos).

Example 6: Automation of the stimulation step, collection of whole blood, stimulation with a specific stimulant (antigens of the Epstein-Barr virus)

The blood samples used in this example were obtained from the French Blood Establishment (EFS, Rhône-Alpes, France). Ten blood samples were collected in sterile Vacutainer® tubes (Becton-Dickinson) containing lithium heparin or equivalent reference from another supplier.

Each blood sample was stimulated according to the "Automated condition according to the invention" protocol detailed in Table 3 of Example 2, using Peptide Epstein-Barr virus (Pep Tivator®) peptides as stimulation agent. . For the NIL condition, the sample was contacted only with PBS.

The results (RFV signal measured by VIDAS® according to the experimental conditions) are given in Table 10 below.

Table 10: Measurement of IFNy by VIDAS®

Results: The protocol for stimulation and detection of the automated immune cell response, without centrifugation and in non-sterile conditions, makes it possible to obtain signals of 7 to 4838 RFV and AG / NIL ratios varying from 0.4 to 131.

Samples 59174878208, 59180477734 and 59180477697 have AG / NIL ratios that vary between 0.4 and 2.0. These ratios are low (<4), which means that secretion of IFNy is not bound to EBV peptides. Therefore, stimulation in automated condition leads to the conclusion that these patients were not infected with the Epstein-Barr virus: negative interpretation (Neg).

Samples 59174878275, 59174878101, 59174878136, 59174878179, 59180477726, 59180477718 and 5918047770- have AG / NIL ratios between 17.9 and 131. These ratios are strong (> 4), which means that the secretion of IFNy is bound specifically peptides of Epstein-Barr virus. Therefore stimulation in automated condition allows to conclude that these patients were infected with the Epstein-Barr virus: positive interpretation (Pos). EXAMPLE 7 Automation of the Stimulation Step, Whole Blood Collection, Non-Specific LPS Stimulation, Molecular Biology Assay

The blood samples used in this example were obtained from the French Blood Establishment (EFS, Rhône-Alpes, France). Five blood samples were collected in sterile Vacutainer® tubes (Becton-Dickinson) containing lithium heparin or equivalent reference from another supplier.

Each blood sample was stimulated according to the protocol "Automated condition according to the invention" detailed in Table 3 of Example 2, using LPS as a stimulating agent. For the NIL condition, the sample was contacted only with PBS.

The detection of the immune cell response by quantification of the mRNAs of the following genes: IFNγ gene, IL1 gene β and ZAP70 gene (bioMérieux internal kit), in the blood samples after stimulation, was performed as follows mRNAs were extracted after lysis of ΙΟΟμί of the reaction mixture using an automated method (BOOM technology). The mRNAs were then amplified by nested RT-PCR in two steps (26 cycles the PCR ^age, followed by a ^2nd PCR of 35 cycles). The actual detection was carried out using an intercalator and the real-time measurements were acquired to construct an amplification curve and obtain a point Cp ("crossing point") for each target and for 3 reference genes (DECR1, PPIB & FPGS). The signal, corresponding to the expression level of the mRNA, was normalized by subtracting the target Cp by a geometric mean of the 3 reference genes.

The results (normalized Cp values ± standard deviation) are given in Table 11 below. The lower the normalized value Cp, the higher the level of expression. Table 11

The results of Table 11 below show that it is possible to detect an immune cell response by molecular biology test after automated stimulation according to the invention.

Bibliographical References

- Almeida CA. M. et al, 2009, Journal of Immunological Methods, 344: 1-5

- Boersma YL and Plutckthun A, 2011, Curr. Opin. Biotechnol, 22: 849-857

- Bustin SA, 2002, Journal of Molecular Endocrinology, 29: 23-39

- Coligan J.E., 1994, Current Protocols in Immunology, Volume I, Supplement 10, Unit 6.19: 1-8

Cox, J.H. et al, 2006, Methods, 38: 274-282

Ellington AD and Szostak JW., 1990, Nature, 346: 818-822

- Gaur RL, et al, 2013, Journal of Clinical Microbiology, 51 (11): 3521-3526

Giulietti A et al, 2001, Methods, 25: 386-401

Handbook of Elispot, 2005, Methods and Protocols, Humana Press Totowa, New Jersey, 1-321

- Keller GH and Manak MM, 1993. DNA Probes, p. 137-196. Stockton Press, Stockton Press

- Kricka LJ, 1999, Nucleic acid detection technologies- labels, strategies, and formats, Clin. Chem. 45, 453-458

- Lalvani, A., 2007, Chest, 131: 1899-1906

Neubauer J.C. et al, 2017, Cytotechnology, 69 (1): 57-73

- Pal M. et al, 2014, Clin. Microbiol. Rev., 27 (1): 3-20

- Rassasie M.J. et al, 1992, Steroids, 57: 112

- General Review, 2003, Ann Biol Clin, 61: 635-44

Stabler T.V. et al., 1991, Clin. Chem., 37 (11): 1987

Uemori T, 2007, J. Biochem. Aug, 142 (2): 283-92

- Vincent et al, 2004, Embo reports, 5 (8): 795-800

- Wood P.R., 1990, Research in Veterinary Science, 49: 46-49

Claims

A method for detecting an immune cell response in a biological sample of animal origin, capable of containing at least one secretory cell of at least one immune effector molecule, comprising the steps of:

2. A method of detecting an immune cell response according to claim 1, characterized in that the secretory stimulant is a nonspecific stimulant or a specific stimulant of a pathogenic microorganism.

3. A method for detecting an immune cell response according to claim 1 or 2, characterized in that said at least one secretory stimulant is a highly specific antigen for Mycobacterium tuberculosis, which may be absent from the BCG vaccine. (Bacille Calmette-Guerin).

4. A method for detecting an immune cell response according to claim 5, characterized in that said at least one secretory stimulant is selected from the antigens ESAT-6, CFP-10 and TB7.7.

5. A method for detecting an immune cell response according to any one of claims 1 to 4, characterized in that said at least one cell is a cell capable of secreting at least one cytokine.

6. A method for detecting an immune cell response according to claim 5, characterized in that said at least one cytokine is selected from interleukins, chemokines, tumor necrosis factor a (TNFa) and interferon gamma (IFNy). ), preferably interferon gamma.

7. A method of detecting an immune cell response according to claim 1 or 2, characterized in that the cells are B cells capable of secreting at least one antibody.

8. A method for detecting an immune cell response according to any one of claims 1 to 7, characterized in that the biological sample is a sample of human origin, bovine, canine, feline or equine.

9. A method of detecting an immune cell response according to any one of claims 1 to 8, characterized in that the incubation step (d) takes place in non-sterile condition.

10. A method of detecting an immune cell response according to any one of claims 1 to 9, characterized in that the container R is non-sterile after introduction of the defined amount of sample.

11. A method of detecting an immune cell response according to any one of the preceding claims, characterized in that the duration of the incubation step is between 2 and 72h.

12. A method for detecting an immune cell response according to any one of claims 1 to 11, characterized in that step (e) implements a binding partner to the immune effector molecule which is a partner of immunoassay and in that the revelation of the binding or not of said molecule is implemented by a sandwich test using another binding partner to the molecule, of different nature or not, one of the two partners being marked.

13. The method of detecting an immune cell response according to claim 1, wherein step (e) uses a binding partner to the immune immunoassay and in that the revelation of the binding or not of said molecule is implemented by a competitive test using a labeled compound competing with said molecule.

14. A method for detecting an immune cell response according to any one of claims 1 to 13, characterized in that the steps (a) to (e) are implemented with the same instrument.

15. A method for detecting an immune cell response according to any one of claims 1 to 14, characterized in that the steps (a) to (e) are implemented successively in the same day.

16. A method for detecting an immune cell response according to any one of claims 1 to 14, characterized in that steps (a) to (d) are implemented on a first day or for several days, and step (e) is implemented then another day.

17. Automated method for stimulating at least one cell capable of secreting an immune effector molecule for the secretion of said molecule, said at least one cell being derived from a biological sample of animal origin, characterized in that it comprises or consists of the steps of:

(a) aspirating a defined (calibrated) amount of the biological sample as withdrawn by an automated suction / discharge device,

18. An automated stimulation method according to claim 17, characterized in that the incubation step (d) takes place in a non-sterile condition.

19. An automated stimulation method according to claim 18 or 19, characterized in that the container R is non-sterile after introduction of the defined amount of sample.

20. Automated stimulation method according to any one of claims 17 to 19, characterized in that the secretion stimulant is a nonspecific stimulant or a specific stimulant of a pathogenic microorganism.

21. Automated stimulation method according to any one of claims 18 to 20, characterized in that the biological sample is a sample of human, bovine, canine, feline or equine origin.

22. Use of a method for detecting an immune cell response according to any one of claims 1 to 16 or the automatic stimulation method according to any one of claims 17 to 21 for the diagnosis of pathologies, for studies toxicity of drugs and vaccines and to determine the immune status of a patient.